The global myocardial infarction market is anticipated to grow at a modest CAGR of around 6.6% during the forecast period. The global myocardial infarction market is primarily driven by the increasing incidence and prevalence rate of chronic diseases, such as diabetes and hypertension along with unhealthy lifestyle changes such as suboptimal diets, excessive consumption of tobacco consumption and alcohol, and sedentary lifestyles. According to WHO, there is an increased risk of myocardial infarction in individuals with smoking habits. The global rise in smokers has increased the risk of heart diseases, it is anticipated to create demand for the myocardial infarction market. According to the Centers for Disease Control and Prevention (CDC), in 2018, nearly 14 of every 100 US adults aged 18 years or older (13.7%) smoked cigarettes. This means an estimated 34.2 million adults in the US currently smoke cigarettes.

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/myocardial-infarction-market

The global myocardial infarction market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into non-ST segment elevation myocardial infarction (NSTEMI) heart attacks, ST-segment elevation myocardial infarction (STEMI) heart attacks, and silent heart attacks. Among these, STEMI held the highest market share in 2020 and is estimated to grow a significant CAGR during the forecast period. STEMI is the most common type of heart attack among all types. The commonly used treatment for STEMI includes percutaneous coronary intervention (PCI), a term that consists of both angioplasty and stenting; clot-busting medication; and coronary artery bypass graft surgery (CABG). Based on the device, the market is segmented into the left ventricular assist device, pacemaker, catheter, implantable cardioverter defibrillator, and others (graft and stent). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT scan), echocardiography, and others. On the basis of treatment, the market is bifurcated into medication and procedure. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.

A Full Report of Global Myocardial Infarction Market is Available at: https://www.omrglobal.com/industry-reports/myocardial-infarction-market

Geographically, the global myocardial infarction market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, the Asia-Pacific market is anticipated to showcase the highest CAGR during the forecast period. Increasing cases related to CVD and heart attack, increasing healthcare infrastructure, and increasing unhealthy lifestyles among people in the region are some of the major factors for the growth of the market in the region. The increasing medical tourism and improving healthcare infrastructure are also contributing significantly to the growth of the myocardial infarction market in the region. The developing economies of Asia-Pacific, especially China, Japan, and India are investing significantly in the development of innovative therapeutic and medical devices.

Global Myocardial Infarction Market– Segmentation
By Type
Non-St-Elevation Myocardial Infarction (NSTEMI)
St-Elevation Myocardial Infarction (STEMI) Heart Attack
Silent Heart Attack
By Device
Left Ventricular Assist Device
Pacemaker
Catheters
Implantable Cardioverter Defibrillator
Others
By Diagnosis
Electrocardiography (ECG)
Chest X-Ray
Computed Tomography (CT scan)
Echocardiography
Others (Blood Test)
By Treatment
Medication
Analgesics
Thrombolytic
Anti-Platelet Agents
Glycoprotein LIB/LIB Inhibitors
Others (Beta-Adrenergic Blockers and Angiotensin-Receptor Blockers)
Surgery
Angioplasty
Coronary Artery Bypass Grafting (CABG)
Heart Transplant
By End-Users
Hospitals and Clinics
Ambulatory Surgical Centers
Research Institutes

Global Myocardial Infarction Market – Segmentation by Region 
North America 
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific 
China
Japan
India
Rest of Asia-Pacific
Rest of the World

Company Profiles
Abbott Laboratories
advanceCOR GmbH.
AstraZeneca PLC
Athersys, Inc.
Bayer AG
BioVascular Inc.
Boehringer Ingelheim International GmbH
Boston Scientific Corp.
Bristol-Myers Squibb, Co.
Caladrius Biosciences, Inc.
Capricor Therapeutics Inc.
CSL Behring
Eli Lilly And Co.
GlaxoSmithKline plc.
GNT Pharma Co., Ltd.
Johnson & Johnson Services Inc.
Koninklijke Philips N.V.
Medtronic Plc
Merck KGaA
Mesoblast Ltd
Mylan N.V.
Novartis AG
NeuroVive Pharmaceutical AB
Osiris Therapeutics Inc.
Pfizer Inc.
PledPharma AB
Portola Pharmaceutical Inc.
Sanofi SA
Siemens AG
Teva Pharmaceutical Industries Ltd.
Ventrix Inc.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/myocardial-infarction-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404